register

News & Trends - Biotechnology

Murdoch Children’s Research Institute to trial preventative vaccine for COVID-19 healthcare workers

Health Industry Hub | March 31, 2020 |
[Total: 1    Average: 5/5]

Professor Kathryn North AC, Director of the Murdoch Children’s Research Institute in Melbourne, Australia, has announced its infectious disease researchers are preparing to roll-out a multi-centre randomised controlled clinical trial of the BCG vaccine against COVID-19.

The trial has been endorsed by the Director-General of the WHO, Tedros Adhanom, who has called for global support and assistance in the fight against COVID-19.  

Professor North said, “Australian medical researchers have a reputation for conducting rigorous, innovative trials. This trial will allow the vaccine’s effectiveness against COVID-19 symptoms to be properly tested, and may help save the lives of our heroic frontline healthcare workers.”

Led by Professor Nigel Curtis, a clinician-scientist who leads MCRI’s Infectious Diseases Research Group, the BRACE trial builds on previous studies which showed that BCG reduces the level of virus when people are infected with similar viruses to SARS-CoV-2. 

Register FREE and join 20,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

Professor Curtis said, “We hope to see a reduction in the prevalence and severity of COVID-19 symptoms in healthcare workers receiving the BCG vaccination.”

“We aim to enroll 4000 healthcare workers from hospitals around Australia, including the Melbourne Campus’ Royal Children’s Hospital to allow us to accurately say whether it can lessen the severity of COVID-19 symptoms. And we need to enroll them in the coming weeks, so the clock is definitely ticking,” said Professor Curtis.

Although originally developed against tuberculosis, and still given to over 130 million babies annually for that purpose, BCG also boosts humans’ ‘frontline’ immunity, training it to respond to germs with greater intensity. 

The researchers hope this improved ‘innate’ immunity will provide crucial time to develop and importantly, validate, a specific anti-SARS-CoV-2 vaccine. 

There are currently no vaccines or other proven preventative therapeutic interventions available to protect health care workers at the frontline exposed to the COVID19 virus. 

The proposed trial is based on an existing MCRI trial, which has allowed rapid but thorough human ethics approvals, and involves sites across Australia. The first sites to be announced is The Royal Children’s Hospital in Melbourne. More sites are expected to be announced in coming days.

Professor North said, “The Federal and State Health Departments, together with Australian and international philanthropists, have shown a willingness and capacity to step up to fund a number of COVID-19 related trials”. 

“Using rapidly sourced and immediately deployable funds, we will be relentless in our pursuit of preventions and treatments for this unprecedented pandemic. These trials will allow the rapid advancement of the most promising candidates to clinical practice, giving us the most number of shots on goal against COVID-19 as possible.”


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Technology levels up support for healthcare employees - Matt Moran, MD, Philips

Technology levels up support for healthcare employees – Matt Moran, MD, Philips

Health Industry Hub | January 22, 2021 |

MedTech News: Matt Moran, Managing Director of Philips Australia & New Zealad, reflects on the impact of the COVID-19 pandemic […]

More


Medical

Aussie researchers receive $2.9m funding boost for multiple sclerosis

Health Industry Hub | January 22, 2021 |

Medical News: Twenty multiple sclerosis (MS) scientific research teams across the country will receive an important New Year funding injection […]

More


News & Trends - Biotechnology

Biotech News - AusBiotech renews agreements with international stakeholders

AusBiotech renews agreements with international stakeholders

Health Industry Hub | January 22, 2021 |

Biotech News: AusBiotech’s international partnerships have been extended, with new Memorandums of Understanding (MoU) signed with major international industry associations […]

More


News & Trends - Pharmaceuticals

Pharma News - AbbVie's phase 3 wins for Humira successor Skyrizi

AbbVie’s phase 3 wins for Humira successor Skyrizi

Health Industry Hub | January 22, 2021 |

Pharma News: AbbVie is in a race against time as patent expiry of its Humira inflammatory diseases blockbuster draws near […]

More